Soleno Therapeutics, Inc.
SLNO
$71.84
-$1.42-1.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.30M | 49.20M | 10.89M | 8.47M | 4.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.79M | 79.34M | 23.23M | 23.07M | 12.83M |
| Operating Income | -58.79M | -79.34M | -23.23M | -23.07M | -12.83M |
| Income Before Tax | -55.98M | -76.62M | -21.85M | -21.40M | -11.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.98M | -76.62M | -21.85M | -21.40M | -11.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.98M | -76.62M | -21.85M | -21.40M | -11.30M |
| EBIT | -58.79M | -79.34M | -23.23M | -23.07M | -12.83M |
| EBITDA | -58.29M | -78.84M | -22.74M | -22.58M | -12.34M |
| EPS Basic | -1.27 | -1.83 | -0.57 | -0.59 | -0.33 |
| Normalized Basic EPS | -0.79 | -1.13 | -0.33 | -0.36 | -0.19 |
| EPS Diluted | -1.27 | -1.83 | -0.57 | -0.59 | -0.33 |
| Normalized Diluted EPS | -0.79 | -1.13 | -0.33 | -0.36 | -0.19 |
| Average Basic Shares Outstanding | 43.92M | 41.88M | 38.63M | 36.21M | 34.44M |
| Average Diluted Shares Outstanding | 43.92M | 41.88M | 38.63M | 36.21M | 34.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |